Patient satisfaction and adverse response from prevention with 240mg galcanezumab of episodic cluster headache

被引:0
作者
Mo, H. [1 ]
Kim, B. K. [2 ]
Moon, H. S. [3 ]
Cho, S. J. [1 ]
机构
[1] Hallym Univ, Dongtan Sacred Heart Hosp, Neurol, Hwaseong Si, Gyeonggi Do, South Korea
[2] Eulji Univ, Nowon Eulji Med Ctr, Neurol, Seoul, South Korea
[3] Kangbuk Samsung Hosp, Neurol, Seoul, South Korea
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P0157
引用
收藏
页码:100 / 101
页数:2
相关论文
共 30 条
[21]   STUDY CGAL: A PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE: RESULTS FROM THE 8-WEEK DOUBLE-BLIND TREATMENT PHASE [J].
Martinez, J. M. ;
Goadsby, P. J. ;
Dodick, D. W. ;
Bardos, J. N. ;
Oakes, T. M. Myers ;
Millen, B. A. ;
Zhou, C. ;
Dowsett, S. A. ;
Aurora, S. ;
Yang, J. Y. ;
Conley, R. R. .
CEPHALALGIA, 2018, 38 :145-146
[22]   Study CGAL: a placebo-controlled study of galcanezumab in patients with episodic cluster headache: results from the 8-week double-blind treatment phase [J].
Martinez, James M. ;
Goadsby, Peter J. ;
Dodick, David ;
Bardos, Jennifer N. ;
Oakes, Tina M. Myers ;
Millen, Brian A. ;
Zhou, Chunmei ;
Dowsett, Sherie A. ;
Aurora, Sheena K. ;
Yang, Jyun Yan ;
Conley, Robert R. .
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[23]   Impact of Galcanezumab on Total Pain Burden: Findings from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache [J].
Kudrow, D. ;
Andrews, J. ;
Rettiganti, M. ;
Oakes, T. M. ;
Bardos, J. ;
Wenzel, R. ;
Kuruppu, D. ;
Gaul, C. ;
Martinez, J. ;
Aurora, S. .
HEADACHE, 2019, 59 :183-183
[24]   Study CGAL: A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase [J].
Martinez, James M. ;
Goadsby, Peter ;
Dodick, David ;
Bardos, Jennifer N. ;
Oakes, Myers Tina M. ;
Millen, Brian A. ;
Zhou Chunmei ;
Dowsett, Sherie A. ;
Aurora, Sheena K. ;
Conley, Robert R. ;
Yang, Jyun Yan .
HEADACHE, 2018, 58 (08) :1289-1290
[25]   Effects of Galcanezumab on Acute Medication Use, Time to Response, and Total Pain Burden in Patients with Episodic Cluster Headache: Post hoc Outcomes from a Phase 3, Randomized, Double-blind, Placebo-controlled Study [J].
Kudrow, David ;
Andrews, J. Scott ;
Rettiganti, Mallikarjuna ;
Oakes, Tina ;
Bardos, Jennifer ;
Zhou, Chunmei ;
Aurora, Sheena K. ;
Kuruppu, Dulanji ;
Wenzel, Richard ;
Riesenberg, Robert ;
Gaul, Charly ;
Martinez, James .
NEUROLOGY, 2020, 94 (15)
[26]   Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine [J].
Ford, Janet H. ;
Foster, Shonda A. ;
Stauffer, Virginia L. ;
Ruff, Dustin D. ;
Aurora, Sheena K. ;
Versijpt, Jan .
PATIENT PREFERENCE AND ADHERENCE, 2018, 12 :2413-2424
[27]   Real-world Use of Non-invasive Vagus Nerve Stimulation for Acute Treatment of Pain in Episodic Cluster Headache: Results from a Patient Registry [J].
Liebler, E. ;
Nagy, A. J. ;
Mwamburi, M. ;
McClure, C. ;
Ailani, J. .
HEADACHE, 2019, 59 :106-106
[28]   Real-world Use of Non-invasive Vagus Nerve Stimulation for Acute Treatment of Pain in Episodic Cluster Headache Attacks: Results From a Patient Registry [J].
Nagy, Abraham ;
Mwamburi, Mkaya ;
McClure, Candace ;
Liebler, Eric ;
Ailani, Jessica .
NEUROLOGY, 2019, 92 (15)
[29]   Changes in Patient Functioning and Disability: Results from Two Phase 3 Double-Blind Placebo-Controlled Clinical Trials Evaluating Galcanezumab for Episodic Migraine Prevention (EVOLVE-1 and EVOLVE-2) [J].
Ford, J. ;
Ayer, D. ;
Zhang, Q. ;
Carter, J. ;
Skljarevski, V ;
Aurora, S. .
HEADACHE, 2018, 58 :171-172
[30]   Changes in patient functioning and disability: results from two phase 3 double-blind placebo-controlled clinical trials evaluating galcanezumab for episodic migraine prevention (EVOLVE-1 and EVOLVE-2) [J].
Ford, Janet H. ;
Ayer, David W. ;
Zhang, Qi ;
Carter, Jeffrey N. ;
Skljarevski, Vladimir ;
Aurora, Sheena K. .
JOURNAL OF HEADACHE AND PAIN, 2018, 19